Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 1/6 |
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥17.88 |
52 Week High | CN¥26.18 |
52 Week Low | CN¥14.81 |
Beta | 0.52 |
11 Month Change | -5.85% |
3 Month Change | -12.78% |
1 Year Change | -30.89% |
33 Year Change | -40.92% |
5 Year Change | 36.54% |
Change since IPO | 88.70% |
Recent News & Updates
Shareholder Returns
2932 | CN Medical Equipment | CN Market | |
---|---|---|---|
7D | -2.9% | -1.9% | -1.9% |
1Y | -30.9% | -15.7% | -15.8% |
Return vs Industry: 002932 underperformed the CN Medical Equipment industry which returned -15.7% over the past year.
Return vs Market: 002932 underperformed the CN Market which returned -15.8% over the past year.
Price Volatility
2932 volatility | |
---|---|
2932 Average Weekly Movement | 5.0% |
Medical Equipment Industry Average Movement | 6.0% |
Market Average Movement | 6.7% |
10% most volatile stocks in CN Market | 10.2% |
10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 002932 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002932's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 1,547 | Chen Li Li | www.mdeasydiagnosis.com |
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, manufacture, and sale of in-vitro diagnostic products China and internationally. Its products portfolio includes molecular diagnostic products, such as PCR system, nucleic acid extraction and purification instrument, and sample release reagent; blood gas analyzer; immuno diagnosis, including chemiluminescence immunoassay, fluorescence immunity, and immunoquantitative analyzer; and automatic coagulation analyzer.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Fundamentals Summary
2932 fundamental statistics | |
---|---|
Market cap | CN¥4.16b |
Earnings (TTM) | CN¥515.33m |
Revenue (TTM) | CN¥3.69b |
8.1x
P/E Ratio1.1x
P/S RatioIs 2932 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2932 income statement (TTM) | |
---|---|
Revenue | CN¥3.69b |
Cost of Revenue | CN¥2.02b |
Gross Profit | CN¥1.67b |
Other Expenses | CN¥1.15b |
Earnings | CN¥515.33m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 2.22 |
Gross Margin | 45.26% |
Net Profit Margin | 13.98% |
Debt/Equity Ratio | 2.2% |
How did 2932 perform over the long term?
See historical performance and comparison